Alexis Biotech

Alexis Biotech was a London-based biotechnology company specializing in the development of immunotherapies for cancer and infectious diseases. The company's core technology focused on the delivery of recombinant HLA/peptide complexes to tumor cells or antigen-presenting cells to trigger T-cell mediated immune responses. In 2009, Alexis Biotech entered into a strategic partnership and cross-licensing agreement with Immunomedics to develop targeted vaccines by combining its HLA-antibody targeting platform with Immunomedics' Dock-and-Lock (DNL) technology. The company's research pipeline primarily targeted indications such as melanoma, chronic lymphocytic leukemia, and HIV/AIDS. Alexis Biotech ceased operations and was officially dissolved in 2015.